港股詳情

本頁面由Tiger Trade Technology Pte. Ltd.提供服務

生物醫藥B類股

502.512

+19.3574.01%

漲家數：24

跌家數：6

平家數：3

市盈率：- -

高：504.211

開：483.278

低：478.821

收：483.155

成交量：1.10億

成交額：29.98億

市值：3,186.42億

流通市值：2,836.43億

資料載入中...

總覽新聞資訊

港股異動 | 科濟藥業-B(02171.HK)早盤漲近5% 香港業務取得重要進展進一步推進愷力美國際化佈局

和鉑醫藥－Ｂ(02142)股價下跌5.004%，現價港幣$13.48

阿斯达克财经

港股異動 | 先健科技(01302)升逾3% LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序

【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善

深港攜手拓全球藥械市場，2026深圳國際高性能醫療器械展舉行

【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升

歸創通橋(02190)出現大手買入85萬股，成交價$23.4，涉資1.989千萬

阿斯达克财经

涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者

國產創新藥新適應症密集獲批「一藥拓多域」重塑行業成長邏輯

歐康維視生物-B：OT-301（NCX 470，比馬前列素格倫諾）在華上市申請獲國家藥監局受理

歐康維視生物-B(01477)：OT-301新藥上市註冊申請獲國家藥品監督管理局受理

第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參

每日经济新闻

勁方醫藥-B(02595.HK)9月10日斥資206.3萬港元回購8萬股

啓明醫療(02500)發新股及換股債集資5億人民幣

阿斯达克财经

同源康醫藥-B(02410.HK)獲董事長吳豫生增持63.5萬股H股涉資約209萬港元

啓明醫療-B(02500.HK)擬向杭州盈智勤三號股權投資合夥企業發行新股及可轉換債券募資不超過5億元

德琪醫藥-B(06996.HK)授出1152萬份受限制股份單位

2026年國家醫保目錄談判收官：「三除外」落地，醫保商保雙軌並行，雙目錄如何重構創新藥支付邏輯

华夏时报网

恒瑞醫藥(01276.HK)自主研發的 1 類創新藥海曲泊帕乙醇胺片獲批新增兩項適應症

信立泰重啓H股IPO，創新藥收入站上半壁江山，仍存單品依賴隱憂

{"basename":"/hant","ssrTDKData":{"titleTemplate":"%s - 老虎證券","title":"老虎證券香港 | 輕鬆買賣美股港股A股/美債/ETF/Crypto/期權期貨","description":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","keywords":"老虎證券,老虎證券開戶,老虎證券香港,老虎證券投資,老虎證券美股,老虎證券登錄,證券開戶,證券公司開戶,股票開戶,香港證券公司,香港證券,證券公司,美股投資平台,小額投資理財,投資app,投資平台,股票買賣,買賣股票平台,炒股app,證券app,新手投資","social":{"ogDescription":"老虎證券香港提供多種優惠: 港股&Crypto 0佣、A股一年0佣、美股期權0佣、IPO抽新股0孖展利息0手續費。美股1美金起投，即時串流報價與多種工具，立即開戶享更多優惠！","ogImage":"https://c1.itigergrowtha.com/portal5/static/media/og-logo.0a0bd8dc.png","ogUrl":"https://www.imtigers.com/hant/stock/BK1574/news?page=5"},"companyName":"老虎證券"},"pageData":{"isMobile":false,"isTiger":false,"isTTM":true,"region":"HKG","license":"TBHK","edition":"fundamental","symbol":"BK1574","isAnalysisPage":false},"__swrFallback__":{"@#url:\"https://hq.skytigris.cn/stock_info/detail/global\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","market":"HK","secType":"PLATE","nameCN":"生物醫藥B類股","latestPrice":502.51205,"timestamp":1789373282104,"preClose":483.15506,"halted":0,"volume":109559454,"delay":0,"changeRate":0.040064,"floatShares":0,"shares":0,"eps":0,"marketStatus":"已收盤","change":19.356995,"latestTime":"09-14 16:00:00","open":483.2777,"high":504.2106,"low":478.82104,"amount":2997572701.5,"amplitude":0.05255,"askPrice":0,"askSize":0,"bidPrice":0,"bidSize":0,"shortable":3,"etf":0,"tradingStatus":0,"nextMarketStatus":{"tag":"開盤","tradingStatus":2,"beginTime":1789435800000},"marketStatusCode":0,"adr":0,"adjPreClose":0,"openAndCloseTimeList":[[1789349400000,1789358400000],[1789362000000,1789372800000]],"pbRate":3.606253,"peRate":160.422718,"turnoverRate":0.004111,"increases":23,"decrements":7,"flats":2,"marketCap":318641943840,"floatMarketCap":283642599432},"@#url:\"https://hq.skytigris.cn/stock_info/fundamental/all\",params:#delay:false,,method:\"POST\",data:#items:@#symbol:\"BK1574\",,,,,undefined,":{"symbol":"BK1574","high":504.2106,"amplitude":0.05255,"preClose":483.15506,"low":478.82104,"pbRate":"3.606253","latestPrice":502.51205,"volume":109559454,"delay":0,"open":483.2777,"prevYearClose":556.26263,"prevWeekClose":483.155,"prevMonthClose":503.398,"prevQuarterClose":453.519,"fiveDayClose":516.325,"twentyDayClose":505.128,"sixtyDayClose":444.911,"secType":"PLATE","market":"HK","turnoverRate":0.004111,"peRate":160.422718,"marketCap":318641943840,"floatMarketCap":283642599432,"timestamp":1789373282104,"nameCN":"生物醫藥B類股"},"@#url:\"https://hq.skytigris.cn/api/global/plate/up_down\",method:\"POST\",data:#delay:false,bkCodes:@\"BK1574\",,,,undefined,":{"bkCode":"BK1574","up":24,"down":6,"flat":3},"$inf$@#url:\"https://stock-news.skytigris.cn/v2/news/list\",params:#symbols:\"BK1574\",pageSize:20,pageCount:5,lang_content:\"cn\",edition:\"fundamental\",,,undefined,":[{"items":[{"id":"2666517233","title":"港股異動 | 科濟藥業-B(02171.HK)早盤漲近5% 香港業務取得重要進展 進一步推進愷力美國際化佈局","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517233","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517233?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 10:12","pubTimestamp":1789092731,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1585","BK1574","02171","BK1587","BK1161"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666457517","title":"和鉑醫藥－Ｂ(02142)股價下跌5.004%，現價港幣$13.48","url":"https://stock-news.laohu8.com/highlight/detail?id=2666457517","media":"阿斯达克财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666457517?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:55","pubTimestamp":1789091700,"startTime":"0","endTime":"0","summary":"[下跌股]和铂医药－Ｂ(02142) 股价在上午09:54比前收市价下跌5.004%，现股价为港币$13.48。至目前为止，今日最高价为$14.01，而最低价为$13.48。总成交量为276.1万股，总成交金额为港币$3.859千万。","market":"sh","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205152747204_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609111606/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAD2609111606/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1574","02142","BK1161","BK1583"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666517543","title":"港股異動 | 先健科技(01302)升逾3% LantvalTM主動脈瓣膜置換系統進入創新醫療器械特別審查程序","url":"https://stock-news.laohu8.com/highlight/detail?id=2666517543","media":"智通财经","labels":["policyRegulatory"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666517543?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:49","pubTimestamp":1789091380,"startTime":"0","endTime":"0","summary":"消息面上，先健科技发布公告，于2026年9月9日，本公司收到国家药品监督管理局的正式书面通知，确认由本公司附属公司深圳市健心医疗科技有限公司与国家心血管病中心中国医学科学院阜外医院联合研发的LantvalTM主动脉瓣膜置换系统进入国家药品监督管理局创新医疗器械特别审查程序。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494794.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"policyRegulatory","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["IEIH","BK1100","159883","BK1574","BK1600","RSPH","09996","PTH","KCAI","01302","BK4588","LGHT","BK1583","MDEV","AGNG","VXUS","HART","GDOC","LNGR","BK4585","MEDX"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666127155","title":"【券商聚焦】中信建投：醫療器械板塊業績有望逐步改善","url":"https://stock-news.laohu8.com/highlight/detail?id=2666127155","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666127155?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:18","pubTimestamp":1789089493,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信建投证券研究指，医疗器械板块Q2收入延续增长趋势，单季度利润增速四年来首次转正。该机构认为，随着集采影响逐步出清叠加创新驱动和海外业务加速的双重助力，医疗器械板块业绩有望逐步改善。尽管季度业绩增速可能有所波动，Q3能否相比Q2加速尚不确定，但大趋势来看，26和27年年度业绩持续改善的确定性较强。","market":"nz","thumbnail":"https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20241108/MDc2YjQxZmY4Y2VkNWEzNDU4MmJiNGExMDgxOTA3MjUwMzc=.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991348","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["01302","00241","BK1247","BK1502","601066","BK1161","BK1584","BK1610","LU0173614495.USD","BK1501","BK1585","BK1100","BK1571","BK1589","BK1615","BK1600","LNGR","LU0287142896.SGD","BK1593","02235","BK1591","RSPH","MEDX","HK0000165453.HKD","LGHT","BK1574","BK1587","BK1617","02252","159883","KCE","BK1515","00853","01066","BK1189","PTH","BK0276","BK1142","HART","09996","BK1222","IEIH","AGNG","BK1583","GDOC","02190","06826","MDEV"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666983512","title":"深港攜手拓全球藥械市場，2026深圳國際高性能醫療器械展舉行","url":"https://stock-news.laohu8.com/highlight/detail?id=2666983512","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666983512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:10","pubTimestamp":1789089045,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["GDOC","HART","LU1152091754.HKD","LU1152091168.USD","RSPH","LU0067412154.USD","SG9999003461.SGD","09996","BK1574","LU0880133367.SGD","159883","00152","BK1507","BK1185","BK1583","LNGR","MEDX","LU1008478684.HKD","LGHT","BK1582","MDEV","PTH","BK1100","IEIH","AGNG"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666917512","title":"【券商聚焦】中信證券：上半年CXO及生命科學上游板塊整體表現穩健，CRO有望量價齊升","url":"https://stock-news.laohu8.com/highlight/detail?id=2666917512","media":"金吾财讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666917512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:07","pubTimestamp":1789088866,"startTime":"0","endTime":"0","summary":"金吾财讯 | 中信证券研究指，2026年上半年，CXO板块及生命科学上游板块整体业绩表现稳健，行业进入复苏阶段。上半年海外投融资景气度持续，美联储加息预期走弱，早研板块整体的景气度持续走强，AIDD的快速发展也将进一步催化未来相关实验和验证需求的爆发，该机构认为CRO板块有望量价齐升。CDMO板块上半年龙头业绩表现稳健，整体订单增速持续加快，行业景气度回升。","market":"other","thumbnail":"https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg","type":0,"news_type":0,"thumbnails":["https://static.szfiu.com/news/20250109/YmQzNzBkZGZmOTg1MzM5MTQzMTA0Ng==.jpg"],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":"299f0a9977df499f8ead781071e5e5e7","theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"1991341","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["06821","WX","03933","01530","LU0244354667.USD","BK0188","06160","09926","LU0540923850.HKD","BK1100","LU0405327494.USD","LU1997245177.USD","LU2328871848.SGD","LU2778985437.USD","LU1997245094.SGD","09688","LU1794554557.SGD","BK1593","06030","LU2476274308.USD","02228","LU0561508036.HKD","LU0348827113.USD","LU0417516902.SGD","BK1500","CXO","LU1146622755.USD","BK0196","LU1969619763.USD","02367","BK1521","SG9999014674.SGD","LU0348783233.USD","LU1188198961.HKD","02196","LU2495084118.USD","02268","LU0463099449.HKD","BK0028","01789","LU0634319403.HKD","LU1720050803.USD","SG9999004311.SGD","01099","600030","IE00B3M56506.USD","BK1574","KURE","LU1997244956.HKD","KCE"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666275512","title":"歸創通橋(02190)出現大手買入85萬股，成交價$23.4，涉資1.989千萬","url":"https://stock-news.laohu8.com/highlight/detail?id=2666275512","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666275512?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 09:01","pubTimestamp":1789088460,"startTime":"0","endTime":"0","summary":"[大手成交]归创通桥(02190)在上午09:01出现大手买入，成交量为85万，成交价为港币$23.4，涉资1.989千万。至目前为止，股价跌1.277%，今日最高价为$23.4，而最低价为$23.4，总成交量为85万股，总成交金额港币$1.989千万。","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20180205145555799_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609111/aamm-all-category","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aamm-content/AAT2609111/aamm-all-category","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["BK1587","BK1574","BK1100","BK1583","02190"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666751737","title":"涉IPO操縱嫌疑，香港證監會強制眼科創新藥公司撥康視雲停牌，最牛天使投資人富豪龔虹嘉是站台的基石投資者","url":"https://stock-news.laohu8.com/highlight/detail?id=2666751737","media":"市场资讯","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666751737?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 08:17","pubTimestamp":1789085820,"startTime":"0","endTime":"0","summary":"停牌前，拨康视云报1.19港元，较2025年7月上市发行价10.1港元，累计蒸发约88%。这是一间成立于2015年、专注眼科创新药的临床阶段生物科技公司，四次递表才闯关成功，上市首日即告破发，如今在监管介入调查中股票停牌，前路未卜。证监会表示，调查仍在进行中，暂不作进一步评论。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://finance.sina.com.cn/stock/hkstock/2026-09-11/doc-inirmfea2271775.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"sina","symbols":["IBBQ","BK1161","06978","REDS","BK1574","159992","KCE","LNGR","MEDX","FRHC","IPOS","BK4127","02592"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666511370","title":"國產創新藥新適應症密集獲批 「一藥拓多域」重塑行業成長邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666511370","media":"格隆汇","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666511370?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:32","pubTimestamp":1789083145,"startTime":"0","endTime":"0","summary":null,"market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.gelonghui.com/rss/live/live.xml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_gelonghui","symbols":["06978","IBBQ","BK1161","MEDX","159992","BK1574","LNGR"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"1104990066","title":"歐康維視生物-B：OT-301（NCX 470，比馬前列素格倫諾）在華上市申請獲國家藥監局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=1104990066","media":"投资观察","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/1104990066?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:13","pubTimestamp":1789081985,"startTime":"0","endTime":"0","summary":"欧康维视生物-B（1477.HK）于9月11日宣布，其核心在研产品OT-301（NCX 470，比马前列素格伦诺）已获中国国家药品监督管理局（NMPA）的新药上市申请（NDA）受理。\n这一进展标志着该创新眼科药物向正式获批上市迈出关键一步。OT-301作为一款新型眼科治疗制剂，其上市申请获得受理，预示着公司有望在中国这一庞大市场中迎来新的增长契机。\n欧康维视生物表示，将继续积极推进OT-301的审评审批进程，力争早日将这一创新疗法带给中国患者。市场分析人士认为，此次NDA获受理对欧康维视生物而言，无疑是一个重要的里程碑事件，有望进一步巩固其在眼科细分领域的竞争优势。","market":"hk","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":null,"symbols":["BK1574","01477","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666197555","title":"歐康維視生物-B(01477)：OT-301新藥上市註冊申請獲國家藥品監督管理局受理","url":"https://stock-news.laohu8.com/highlight/detail?id=2666197555","media":"智通财经","labels":["productRelease"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666197555?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:09","pubTimestamp":1789081743,"startTime":"0","endTime":"0","summary":"智通财经APP讯，欧康维视生物-B 发布公告，OT-301作为降低开角型青光眼或高眼压症患者的眼内压疗法的新药上市注册申请已获中华人民共和国(中国)国家药品监督管理局药品审评中心受理，并获Mont Blanc试验及Denali试验的数据支持。其为一种由Nicox发明的新化学实体，旨在释放贝美前列素及一氧化氮，用于降低开角型青光眼及高眼压症患者的IOP。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.zhitongcaijing.com/content/detail/1494740.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"productRelease","news_rank":0,"length":0,"strategy_id":0,"source":"stock_zhitongcaijing","symbols":["BK1574","BK1191","IPOS","01477"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666519701","title":"第七批國家組織醫用耗材集中採購開標；諾華大股東呼籲改組董事會｜醫藥早參","url":"https://stock-news.laohu8.com/highlight/detail?id=2666519701","media":"每日经济新闻","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666519701?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 07:01","pubTimestamp":1789081313,"startTime":"0","endTime":"0","summary":"丨2026年9月11日星期五丨NO.1爱康医疗宣布提高股东股息分派占归母净利比例9月10日，爱康医疗基于对集团未来业绩及长期发展前景的信心，宣布股东股息分派及回报计划，截至2026年12月31日止财政年度，年度股息派付比例提高至不低于归母净利润的55%；截至2027年12月31日及2028年12月31日止财政年度各年，派息比例提升至不低于归母净利润的60%。","market":"us","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609113871018788.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609113871018788.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"-1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IE00B4R5TH58.HKD","BK1161","159938","BK4007","IE0002141913.USD","BK4532","IE0009355771.USD","LU0208291251.USD","MEDX","IE00BJT1NW94.SGD","BK1515","IE00BJJMRZ35.SGD","BK1574","NVS","BK4578","09939","IE00B2B36J28.USD","IE00BFTCPJ56.SGD","LU0211331839.USD","BK4585","BK4588","LU0320765489.SGD","LU0070302665.USD","PPH"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666251945","title":"勁方醫藥-B(02595.HK)9月10日斥資206.3萬港元回購8萬股","url":"https://stock-news.laohu8.com/highlight/detail?id=2666251945","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666251945?lang=zh_tw&edition=fundamental","pubTime":"2026-09-11 06:59","pubTimestamp":1789081141,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1515","BK1574","BK1161","02595","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666590952","title":"啓明醫療(02500)發新股及換股債集資5億人民幣","url":"https://stock-news.laohu8.com/highlight/detail?id=2666590952","media":"阿斯达克财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666590952?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 22:49","pubTimestamp":1789051740,"startTime":"0","endTime":"0","summary":"<汇港通讯>         启明医疗(02500)宣布，建议发行新股及可转换债券，集资5亿元人民币。配售股份约1.845亿股。占扩大后股本约29.5%，配售价每股1.078港元，较9月10日收市价每股1.17港元折让约7.9%，代价1.719亿元人民币。可转换债券本金额3.797亿港元，初步转换价每股1.1858港元，较9月10日收市价溢价约1.4%。认购所得款项总额约5亿元人民币，净额约4.765亿元人民币，其中约25.2%用于支付研发、临床及监管费用；约43.3%补充一般企业营运资金需求；约31.5%用作偿还未偿还贷款。 (WH)新闻来源 (不包括新闻图片): 汇港资讯","market":"hk","thumbnail":"https://plib.aastocks.com/aafnnews/image/medialib/20201222151859290_s.jpg","type":0,"news_type":0,"thumbnails":["https://plib.aastocks.com/aafnnews/image/medialib/20201222151859290_s.jpg"],"rights":{"source":"aastocks_highlight","url":"http://www.aastocks.com/tc/stocks/news/aafn-con/IC4989087/latest-news/INFOCAST","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://www.aastocks.com/tc/stocks/news/aafn-con/IC4989087/latest-news/INFOCAST","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"aastocks_highlight","symbols":["CNHmain","MCNHmain","UCmain","BK1583","BK1574","02500","BK1100","MUCmain","CYB"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666594669","title":"同源康醫藥-B(02410.HK)獲董事長吳豫生增持63.5萬股H股 涉資約209萬港元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666594669","media":"中金财经","labels":["shareholding"],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666594669?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 22:47","pubTimestamp":1789051624,"startTime":"0","endTime":"0","summary":"格隆汇9月10日丨同源康医药-B(02410.HK)公告，公司董事长、执行董事兼总裁吴豫生已告知公司，于2026年9月8日至2026年9月10日期间，其于公开市场购入63.5万股公司H股(占公司已发行股本总额约0.17%)，总代价约为209万港元。吴豫生已告知公司，其未来可能继续根据市场情况购买公司股份。目前预计其将在此基础上进一步购买股份的总金额不超过300万港元。","market":"fut","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://sc.stock.cnfol.com/gushizhibo/20260910/32366677.shtml","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"1","news_top_title":null,"news_tag":"shareholding","news_rank":0,"length":0,"strategy_id":0,"source":"zhongjincaijing_highlight","symbols":["BK1515","BK1574","02410","159938","BK1161","09939"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666967845","title":"啓明醫療-B(02500.HK)擬向杭州盈智勤三號股權投資合夥企業發行新股及可轉換債券 募資不超過5億元","url":"https://stock-news.laohu8.com/highlight/detail?id=2666967845","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666967845?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 21:20","pubTimestamp":1789046454,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["02500","BK1583","BK1574","BK1100"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666938635","title":"德琪醫藥-B(06996.HK)授出1152萬份受限制股份單位","url":"https://stock-news.laohu8.com/highlight/detail?id=2666938635","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666938635?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 20:04","pubTimestamp":1789041856,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1574","BK1583","06996","BK1191"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666560028","title":"2026年國家醫保目錄談判收官：「三除外」落地，醫保商保雙軌並行，雙目錄如何重構創新藥支付邏輯","url":"https://stock-news.laohu8.com/highlight/detail?id=2666560028","media":"华夏时报网","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666560028?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 19:12","pubTimestamp":1789038763,"startTime":"0","endTime":"0","summary":"9月9日正午，北京西黄城根北街2号全国人大会议中心。最后一家参与商保创新药目录价格协商的企业代表走出大门，历时五天的2026年国家医保目录现场谈判竞价与商保创新药目录价格协商正式收官。新版国家基本医保药品目录与商保创新药目录预计今年11月公布，2027年1月1日起统一执行。五天时间里，124个目录外药品先后完成基本医保谈判竞价，12个创新药冲击商保创新药目录价格协商。","market":"sh","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":{"source":"stock_eastmoney","url":"http://finance.eastmoney.com/a/202609103870706515.html","rn_cache_url":null,"directOrigin":true},"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"http://finance.eastmoney.com/a/202609103870706515.html","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"stock_eastmoney","symbols":["IBBQ","BK1161","MEDX","BK1574","LNGR","159992","06978"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666856717","title":"恒瑞醫藥(01276.HK)自主研發的 1 類創新藥海曲泊帕乙醇胺片獲批新增兩項適應症","url":"https://stock-news.laohu8.com/highlight/detail?id=2666856717","media":"智通财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666856717?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 18:48","pubTimestamp":1789037303,"startTime":"0","endTime":"0","summary":null,"market":"hk","thumbnail":null,"type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.zhitongcaijing.com/immediately.html?type=ganggu","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"live_zhitongcaijing","symbols":["BK1161","LU0359202008.SGD","BK1574","LU0359201612.USD","BK1191","01276","06978","LU2543165471.USD","LU1023057109.AUD","LU0359201885.HKD"],"isVideo":false,"video":null,"gpt_icon":0},{"id":"2666648561","title":"信立泰重啓H股IPO，創新藥收入站上半壁江山，仍存單品依賴隱憂","url":"https://stock-news.laohu8.com/highlight/detail?id=2666648561","media":"蓝鲸财经","labels":[],"top":-1,"itemType":null,"share":"https://ttm.financial/m/news/2666648561?lang=zh_tw&edition=fundamental","pubTime":"2026-09-10 17:29","pubTimestamp":1789032552,"startTime":"0","endTime":"0","summary":"业务层面，信立泰转型取得阶段性成果的同时，核心产品收入集中的风险始终悬而未决。作为转型最重要的产品，信立坦2024 年销售额约 15 亿元，是公司创新药板块最主要的收入来源，公司创新药板块收入高度依赖这一款降压药物。虽然后续信超妥、复立坦、复立安等多款创新产品陆续获批、纳入医保，形成产品梯队，但是这些新产品体量尚小，短期内难以替代信立坦的收入贡献，公司仍然处于单品依赖阶段。","market":"sh","thumbnail":"","type":0,"news_type":0,"thumbnails":[],"rights":null,"property":[],"language":"zh","translate_title":"","themeId":null,"theme_name":"","theme_type":"","isJumpTheme":false,"source_url":"https://www.lanjinger.com/d/1789029785904368871","is_publish_highlight":false,"source_rank":0,"column":"","sentiment":"0","news_top_title":null,"news_tag":"","news_rank":0,"length":0,"strategy_id":0,"source":"lanjinger_stock","symbols":["BK0188","BK0196","BK4127","IPOS","FRHC","002294","KCE","MEDX","BK0028","BK1161","BK0239","IBBQ","BK1574","06978","BK0183","159992","BK0187","LNGR","REDS"],"isVideo":false,"video":null,"gpt_icon":0}],"pageSize":20,"totalPage":18,"pageCount":5,"totalSize":359,"code":"91000000","status":"200"}]}}